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Summary The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro
by using a culture of the IGROVI human ovarian cancer cell line. Disappearance of pharmacologically active
unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and
CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell
survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant
differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP
between the three dose-input functions (AUC i.v. bolus, 6.34 ± 0.36; 3 h infusion, 6.35 ± 0.59; and 20 h
infusion, 6.76 ± 0.40pg h ml-'). Also, the differences between the area under the CDDP-DNA adduct-time
curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the
CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h
infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These
relationships were not significantly different between the three dose-input functions. Variation in the rate of
input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell
survival.
CDDP is one of the most potent cytotoxic compounds in vivo
and is used frequently for the treatment of ovarian and
testicular cancer, head and neck cancer and other malignan-
cies (Loehrer & Einhorn, 1984; Forastiere et al., 1987; Reed
et al., 1988a; 1990). Its application is accompanied by dose-
limiting side-effects, such as nephro-, neuro- and ototoxicity
(Kovacs et al., 1982; Meijer et al., 1983; Vermorken et al.,
1983). Despite its long-standing and wide clinical application,
the optimal schedule of CDDP, with a maximal attainable
anti-tumour effect and tolerable side-effects, has never been
clearly established. From early studies it became evident that
a rapid i.v. infusion was associated with the development of
profound, and sometimes irreversible, nephrotoxicity.
Because of this infusion times were prolonged, with intensive
pre- and post-hydration and administration of CDDP in
saline solutions (Jacobs et al., 1978; Salem et al., 1984;
Vogelzang, 1984), rendering side-effects more manageable.
The influence of the variation of the rate of input (i.e.
dose-input function per treatment cycle) on the cytotoxic
activity of CDDP is less clearly defined. Clinical observations
suggest that the anti-tumour effect is not influenced by the
dose-input function (Vermorken et al., 1982).
Data on the pharmacokinetic-dynamic relationships of
CDDP in clinical and preclinical studies, taking the CDDP-
DNA adduct formation and repair and exposure to unbound
CDDP into consideration, are lacking.
CDDP binds almost irreversibly to plasma and cellular
components (Yotsuyanagi et al., 1991). This results in an
extremely long retention of CDDP in tissues (Loehrer &
Einhorn, 1984). The elimination half-life of the pharma-
cologically active unbound CDDP in the plasma is short and
is approximately 1 h in man (Vermorken et al., 1982, 1986).
The cytotoxic activity of CDDP is very likely correlated to
the covalent binding to DNA, so-called inter- and intrastrand
adduct formation (Plooy et al., 1984). This is not an irre-
versible process because of the cellular capacity to remove
the formed adducts (DNA repair) (Plooy et al., 1984;
Fichtinger-Schepman et al., 1987).
Variation in the dose-input function results in a different
shape of the plasma concentration-time curve of unbound
CDDP. Because of the diffusion of CDDP to tumour tissues,
this will also result in different concentration-time curves at
the site of action. If one assumes linear pharmacokinetics, i.e.
the magnitude of the AUC is not dependent on the dose-
input function, then variation in the dose-input function will
only lead to differences in the shape of the AUC.
In the present study the kinetics of CDDP-DNA adduct
formation and repair was studied in vitro as a function of the
variation in the dose-input of CDDP, using a well-
characterised IGROVl ovarian cancer cell line. The profiles
of an i.v. bolus and 3 h and 20 h infusion were simulated in
vitro and the pharmacokinetics of unbound CDDP was cor-
related to the CDDP-DNA adduct formation and repair and
tumour cell survival (i.e. pharmacodynamics).
Materials and methods
Chemicals
Roswell Park Memorial Institute (RPMI) 1640 medium was
obtained from Brunschwig (Amsterdam, The Netherlands),
bovine calf serum (BCS) from Hyclone (Logan, UT, USA),
dimethylsulphoxide (DMSO) and platin (Pt) standard solu-
tion (500 p.p.m.) from Baker (Deventer, The Netherlands),
phosphate-buffered saline (PBS) from Boom (Meppel, The
Netherlands) and insulin Neerlandicum from Organon (Oss,
The Netherlands). Streptomycin, penicillin, gentamycin,
glutamine and trypsin were obtained from Gibco (Breda, The
Netherlands), DNAse I from Sigma (St Louis, MO, USA),
proteinase K and caesium chloride from Merck (Darmstadt,
Germany), and sodium dodecyl sulphate (SDS) and haema-
toxylin from Brunschwig (Amsterdam, The Netherlands).
Ethylenediaminetetraacetic acid (EDTA) and all other
chemicals were obtained from Baker and were of analytical
grade or higher. T25 (25 cm2), T75 (75 cm2) and T175
(162 cm2) culture flasks were obtained from Costar (Bad-
hoevedorp, The Netherlands).
IGROVI cell culture
The IGROVI ovarian adenocarcinoma cell line was
originated by J. Benard (Institut Gustave Roussy, Villejuif,
France (Benard et al., 1985; Teyssier et al., 1989) and kindly
supplied by R.L.H. Bolhuis (Rotterdam Cancer Institute,
Rotterdam, The Netherlands). The cell line was maintained
in a continuous logarithmic culture in RPMI-1640 medium
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with HEPES and phenol red supplemented with 10% BCS,
10 mM sodium bicarbonate, 2 mM glutamine, penicillin
111 IU ml', streptomycin 103 g ml1', gentamycin
43pg ml-' and insulin 10jig ml-'. The cells were cultured at
37°C in a humidified atmosphere of 5% carbon dioxide in
air. The cells were mildly trypsinised for passage and for use
in experiments. The cloning efficacy and cell doubling time
were determined. For the latter the sulphorhodamine B
(SRB) test was used.
Apparatus
A flameless Perkin-Elmer 3030B atomic absorption spect-
rophotometer (AAS) was used equipped with an AS60 auto-
sampler and HGA600 controller system (Uberlingen,
Germany). The UV spectrophotometer was a Backman
DU62 (Fullerton, CA, USA) set at 260 nm.
Assay ofCDDP in the culture medium
Total and unbound CDDP were analysed by AAS. One
millilitre of medium was taken for the analysis of the total
and unbound CDDP concentration. For the total CDDP
concentration, 100 lI was taken and diluted 10-40 times
with 0.2% Triton X-100 containing 0.06% caesium chloride
in order to obtain CDDP concentrations in the range
10-100 ngml'. Unbound CDDP was analysed after depro-
teination of 0.5 ml of the medium sample with 1.0 ml of
ice-cold absolute ethanol. A volume of 250 jAI was taken and
diluted 10-40 times with deionised water. A volume of 50 tll
was injected into the AAS. All measurements were carried
out in duplicate.
Assay ofDNA levels in tumour cells
DNA levels in tumour cells were determined according to a
method described by Fichtinger-Schepman et al. (1987).
Analysis ofCDDP-DNA adduct levels
CDDP-DNA adduct levels were quantitated according to a
method described by Reed et al. (1988b) with modifications.
Briefly, a DNA sample was digested with DNAse I and zinc
chloride (10 iM, 10 .l) was added to the mixture to optimise
the enzymatic reaction (Fichtinger-Schepman et al., 1987). A
volume of 160 .l (approximately 60-250 lg of DNA) was
injected into the furnace using the 4 x multiple sampling
feature of the instrument. The samples were calibrated on a
standard curve of four samples with a Pt concentration of 0,
1.5, 3, 6 ng ml-1' (equivalent to 0, 240, 480, 960 pg of Pt in
the injected volume of 160fd). CDDP-DNA adduct levels
were expressed as pg of Pt per tLg of DNA (pg Ptpg 'DNA).
The analysis was carried out in duplicate.
CDDP-protein binding experiment
CDDP (10tLgml-') was incubated for 24 h at 37°C with
human plasma (15 ml) and a 7% (v/v) human albumin solu-
tion in RPMI-1640, containing 10% BCS (total volume of
the mixture, 15 ml). During the incubation period total and
unbound CDDP were analysed at 0, 0.5, 1, 2, 3, 5, 8 and
24h.
Influence ofprotein binding on the CDDP-DNA adduct
formation
In order to study the relationship between the unbound
CDDP and adduct formation, IGROVI cells were incubated
with CDDP in three different experiments.
1. A volume of 5 ml of PBS was added to each of three T75
flasks containing the cell culture in 10 ml of RPMI-1640.
Subsequently CDDP was added.
2. Instead of PBS, 5 ml of a 20% albumin solution was
added, immediately followed by CDDP.
3. CDDP was preincubated with 5 ml of the 20% albumin
solution at 37°C for 24 h and added to the cell culture.
The final concentration of CDDP in each flask was
5ILgml-'. All experiments were carried out in triplicate.
At 1, 2 and 4 h after the start of the incubation a flask
was taken and analysed for total and unbound CDDP
and the CDDP-DNA adduct level.
Design ofthe simulation oftheprofiles ofan i.v. bolus and 3 h
and 20 h infusions
Intravenous bolus profile Six T175 culture flasks containing
approximately 6 x 106 cells in 16 ml of medium were used for
the concentration-time and adduct-time curves. An 8 ml
aliquot of albumin was added immediately followed by 90 tlI
of a CDDP solution of 1 mg ml-'. The final albumin concen-
tration in the mixture was then 7%. After 3 h the medium
was carefully removed and the cells were washed twice with
PBS and cultured again in CDDP-free medium. At 1, 3, 8,
20, 44 and 68 h from the start a flask was used to harvest
cells for measurement of the CDDP-DNA adduct level. Dur-
ing the incubation 1 ml of medium was taken at 0, 0.5, 1, 2
and 3 h for measurement of the concentration of total and
unbound CDDP.
Three hour infusion profile Every 15min for lh a small,
but constant, amount of CDDP (18.41l containing
0.2 mg ml-' CDDP) was added to the 16 ml of culture
medium. After another 1l h of incubation 8 ml of 20%
albumin was added to the flask immediately followed by
CDDP (51.21Al of a solution of 0.2mg ml' CDDP), to
prevent dilution of CDDP in the flask owing to the addition
of the relatively large volume of albumin solution. Five hours
later (8 h from the start) the medium was removed and the
cells were washed and cultured again as outlined. The same
CDDP-DNA adduct time points were determined as in the
i.v. bolus experiment. During the incubation 1 ml of medium
was taken at 0, 0.5, 1, 2, 3 and 8 h for measurement of the
total and unbound CDDP concentration.
Twenty-hour infusion profile Seven flasks were used. CDDP
was added at time point 0 h, and after 20 h the medium was
removed. Subsequently, the cells were washed and cultured as
outlined. The CDDP-DNA adduct time points were 1, 3, 8,
20, 24, 44 and 68 h. Total and unbound CDDP were deter-
mined at 1, 3, 8 and 20 h, as outlined. All experiments are
carried out in quadruplicate. The three experiments were
further denoted as i.v. bolus and 3 h and 20 h infusions.
Cell survival measurement
The clonogenic assay was used. Exponentially growing
IGROVI cells in RPMI-1640 were plated in T25 culture
flasks (in 4 ml of medium), with a density range of 5 x 102 to
105 cells, 24 h before CDDP administration. The same proce-
dure of CDDP incubation and albumin addition was fol-
lowed as outlined above. In the i.v. bolus experiment indivi-
dual flasks were taken after 1, 2 and 3 h of incubation, in the
3 h infusion experiment after 1, 3 and 8 h of incubation, and
in the 20 h infusion after 1, 3, 8 and 20 h of incubation. The
medium was removed and the cells were washed twice with
PBS and cultured again in CDDP-free medium for approxi-
mately 2 weeks. Subsequently, the colonies were fixed with
absolute methanol-acetic acid (17 M) (2:1, v/v) and stained
with haematoxylin. Colonies of > 50 cells were counted. All
experiments were carried out in quadruplicate.
Pharmacokinetic and statistical analysis
The AUC of unbound CDDP in the medium and AUA (up
to 68 h) in the tumour cells were calculated using the
trapezoidal method. The initial slope, after withdrawal of
CDDP, was calculated between the adduct time points
3-20 h (i.v. bolus, three adduct time points), 8-20 h (3 h
infusion, two points) and 20-44 h (20 h infusion, three
points). Student's t-test, the Kolmogorov-Smirnov (KS) test860 J. MA et al.
and log-linear regression analysis were used. Student's t-test
was used if at least four observations were evaluable and the
standard deviations per treatment group were <400%
different, otherwise the non-parametric KS test was applied.
Results
Igrovl cell culture (IGROVI)
The cloning efficacy was 20 ± 4%. The cell doubling time
was 24 ± 3 h.
CDDP-protein binding experiment
The binding of CDDP to proteins in human plasma was
similar to the binding to proteins in the mixture of RPMI-
1640 containing human albumin (Figure 1). After 1 h ap-
proximately 50% of CDDP was bound in both experiments.
After 24 h only 3% was unbound.
In the protein-free medium there was a linear increase in
adduct formation with time (Figure 2). Addition of albumin,
immediately followed by CDDP, resulted in a significantly
lower increase in adducts with time. When CDDP was prein-
cubated with albumin, thereby eliminating unbound CDDP,
no significant adduct formation was observed.
Assay ofCDDP in the culture medium
Total and unbound CDDP could be analysed reproducibly in
the observed concentration range 0.1-5 fig ml-'. Coefficients
of variation were <5%. The measured concentration-time
curves of total and unbound CDDP in the three experiments
are given in Figure 3. The profiles of unbound CDDP in the
simulated i.v. bolus and 3 h and 20 h infusions were not
significantly different from those expected in plasma. The
elimination half-life of unbound CDDP in the i.v. bolus
experiment was 1.5 ± 0.20 h, and in the 3 h infusion experi-
ment 1.7 ± 0.20 h (not significantly different). In the i.v.
bolus experiment only 22% of CDDP was unbound after 3 h
of incubation. In the 20 h infusion experiment 55% was
unbound after 20 h of incubation (Figure 3). The Cmax of
CDDP was highest in the i.v. bolus and lowest in the 20 h
infusion experiment (Table I). The AUC values of the three
dose-input functions were not significantly different.
Analysis ofDNA and CDDP-DNA adduct levels
CDDP-DNA adduct levels could be determined reproducibly
in the observed range 0.5-15 pg Pt jig`DNA. The coefficient
of variation was 20% at 1.5ngml-'Pt (240pg of Pt per
injected sample) and 8% at higher concentrations. The detec-
tion limit was 100 pg of Pt per sample.
The maximal adduct levels (Amax) were reached at the end
of the incubation with CDDP (Figure 4). The differences
between the three experiments were not significant (Table I),
although there appeared to be a rank order, with the i.v.
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Figure 2 Relationship between the exposure of CDDP
(5 fig ml-') and CDDP-DNA adduct levels in the IGROVI cell
line. a, CDDP in RPMI-1640 medium with 6 x 106 cells. b,
CDDP in a 7% solution of human albumin in RPMI-1640. c,
CDDP was preincubated with human albumin for 24 h and
added to RPMI-1640. 'P<0.05; *'P<0.01 (a compared with b);
"*P<0.01 (c compared with b). NS, not significant.
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Figure 1 Protein binding of CDDP (10 sg ml-') in human
plasma (0) and in a 7% solution of human albumin in RPMI-
1640 (+). Incubation at 37°C.
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Figure 3 Total and unbound CDDP of the three dose-input
functions. A, A, total and unbound CDDP of the i.v. bolus; *,
0, total and unbound CDDP of the 3 h infusion; *, 0, total
and unbound CDDP of the 20 h infusion.
Table I Pharmacokinetic and dynamic data of CDDP in vitro (mean ± s.d. of four observations)
C.." AUC A, AUC Initial slope
Dose-input (Isgmlb) (ig hml') (pg Pt Lg-I DNA) (pg PthlAg- DNA) (%)
Intravenous bolus 4.23 ± 0.12a 6.33 ± 0.36 8.8 ± 0.9 293 ± 32 21 + Ib,c
Three hour infusion 1.47 ± 0.03 6.34 ± 0.59 8.5 ± 0.7 271 ± 10 31 ± gb
Twenty hour infusion 0.52 ± 0.05 6.76 ± 0.40 7.4 ± 1.2 319 ± 49 13 ± I
NS NS NS
ap <0.05: 0.52<1.47<4.23, bp<0.05 compared with 20 h infusion, cP = 0.07 compared with 3 h infusion. NS, not
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Figure 4 CDDP-DNA adduct-time curves of the three dose-
input functions. (+) Intravenous bolus; (0) 3 h infusion; (0)
20 h infusion. P<0.01: i.v. bolus significantly higher than 3 h
infusion and 3 h infusion significantly higher than 20 h infusion.
**P<0.01: i.v. bolus and 3 h infusion significantly higher than
20 h infusion. **P<0.01: 20 h infusion significantly higher than
i.v. bolus and 3 h infusion. "'*P<0.05: 20 h infusion significantly
higher than i.v. bolus and 3 h infusion.
bolus having the highest and the 20 h infusion experiment the
lowest Amax level. Also, the AUA values, calculated up to
68 h, were not significantly different between the experiments.
The initial decline in the adduct-time curve (initial slope in
Table I) was significantly more rapid in the i.v. bolus and 3 h
infusion than in the 20 h infusion experiment.
Cell survival measurement
The decline in cell survival with time was highest in the i.v.
bolus and lowest in the 20 h infusion experiment (Figure 5).
A log-linear relationship was observed between the decline in
the cell survival and the AUC of unbound CDDP (Figure 6).
The slopes of the three dose-input functions were not
significantly different (Figure 6). The log-linear slope of the
i.v. bolus experiment was 12.9 ± 0.13, of the 3 h experiment
13.2 ± 0.66 and of the 20 h experiment 11.7 ± 0.53 (all n = 3;
not significantly different).
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Figure 5 Influence of the three dose-input functions of CDDP
on cell survival of IGROVI tumour cells in the clonogenic assay.
(+) Intravenous bolus; (0) 3 h infusion; (0) 20 h infusion.
*P<0.01: 20 h infusion significantly higher than 3 h infusion and
3 h infusion significantly higher than i.v. bolus. "P<0.05: 20 h
infusion significantly higher than 3 h infusion.
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Figure 6 Log-linear relationship between the AUC of unbound
CDDP of the three dose-input functions of CDDP and cell
survival. (+) Intravenous bolus; (0) 3 h infusion; (0) 20 h
infusion.
Discussion
In the present study relationships were established between
the exposure to unbound CDDP, CDDP-DNA adduct
kinetics and tumour cell survival. To assess these relation-
ships former and presently used clinical dose-input functions
were simulated in vitro, using a cell culture of the IGROVI
human ovarian cancer cell line.
After administration to patients, unbound CDDP is elimi-
nated by irreversible protein binding and renal elimination.
The clearance by protein binding exceeds renal clearance of
unbound CDDP by a factor of approximately 4-5 (Bajorin
et al., 1986). Irreversible protein binding can easily be
simulated in vitro, as is illustrated in Figure 1. Human
albumin was added to the RPMI-1640 culture medium of the
IGROVI cell line as outlined. The results show that the
protein binding kinetics in this mixture and in human plasma
are similar. The concentration range of CDDP in vitro in the
present study was of the same order as is observed in plasma
of patients after administration of a dose of approximately
80 mg m-2 (Vermorken et al., 1986). The elimination kinetics
of CDDP in vitro, using the outlined approach, reflects the
kinetics in vivo (Vermorken et al., 1982, 1986). The elimina-
tion half-life is slightly longer because of the absence of renal
clearance. In the present model the remaining low concentra-
tion of unbound CDDP was removed from the medium after
3, 8 and 20 h in the i.v. bolus, 3 h and 20 h experiment
respectively, to prevent low remaining concentrations of
unbound CDDP and to facilitate the calculation of the
AUC.
The simulation of the clinical dose-input functions of
CDDP in vitro has some limitations. The cell line is exposed
to concentration-time profiles of CDDP which are observed
in vivo in the blood compartment. This profile may be
different from the in vivo exposure of tumour cells in solid
tumours in peripheral tissues in patients. The concentration
of unbound CDDP to which the tumour cells are exposed in
the in vitro model will be slightly different from the concent-
ration in the tumour in patients, because no steady state has
been reached after a single CDDP administration. Another
limitation of the model is associated with the use of a
logarithmic growing cell culture instead of the use of a solid
tumour. However, because of the similarities between the
pharmacokinetics of unbound CDDP in vivo in patients and
in vitro in the present model, the model is considered ap-
propriate for the assessment of pharmacokinetic-dynamic
relationships of unbound CDDP, despite the outlined restric-
tions.
Protein-bound CDDP is not able to form CDDP-DNA
adducts, which is illustrated in Figure 2. Hence unbound
CDDP should be used for the assessment of the pharmaco-
kinetic-dynamic relationship. In the light of this observation
it should be realised that clinical trails which use CDDP862 J. MA et al.
preincubated with albumin (Holding et al., 1992) may not
lead to significant anti-tumour responses.
The design of the simulation of the three dose-input func-
tions resulted in non-significant differences in the AUC of
unbound CDDP. This is an ideal starting point to assess the
influence of the rate of input of CDDP on CDDP-DNA
adduct formation and repair and cell survival.
The Am.x in the three experiments was not significantly
different, although the level in the i.v. bolus and 3 h infusion
was slightly higher than in the 20 h infusion. The AUA was
clearly not significantly different in the three dose-input func-
tions. This illustrates that the rate of input of CDDP does
not influence the magnitude of the adduct formation.
The initial rate of decline of the adduct-time curve was
significantly lower in the 20 h infusion. The rate of decline
was studied in all experiments after withdrawal of CDDP. It
is not clear what mechanism caused the difference. Further-
more, the increase in the adduct formation with time in the
20 h infusion experiment is clearly non-linear (Figure 4).
However, the experimental design does not permit assessment
of differences in adduct removal during the period of CDDP
exposure. The observed differences in the adduct kinetics had
no implications for cell survival (Figure 6). This seems to be
in contrast to the results of the Troger et al. (1992). They
found that the longest exposure time of total CDDP in a
head and neck cancer cell line resulted in the lowest cytotoxi-
city. However, protein binding of CDDP in the culture
medium was not taken into account and no adduct levels
were determined. Correction for the unavoidable protein
binding of CDDP might have changed the results of that
study.
The log-linear relationship between the AUC of unbound
CDDP and cell survival was strikingly similar in the three
dose-input functions. This implies that cell kill is determined
not by the rate of input of CDDP, but by the magnitude of
the exposure to unbound CDDP. If these results are con-
firmed in other tumour models, then they may have signifi-
cant implications in designing optimal modes of clinical
CDDP administration.
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